Phase 1b/2 Trial Testing Rebastinib/Chemo Combo in Advanced Cancer Patients Begins

Phase 1b/2 Trial Testing Rebastinib/Chemo Combo in Advanced Cancer Patients Begins
A Phase 1b/2 clinical trial testing rebastinib, in combination with the chemotherapy medication carboplatin, in adults with breast cancer and patients with other advanced or metastatic solid tumors has begun, Deciphera Pharmaceuticals announced. Recruitment for this open-label, multicenter study is ongoing at NEXT Oncology in San Antonio, but has yet to start at the MD Anderson Cancer Center in Houston. More information can be found here. The study will be conducted in two parts. Part 1 will assess the safety, tolerability, and pharmacokinetics — a compound’s absorption, distribution, metabolism, and excretion in the body — of twice-daily doses of rebastibinib — 50 mg and 100 mg — in combination with carboplatin, delivered intravenously (into the vein). Rebastinib will be given orally, either in 25 or 75 mg tablets, in 21-day cycles. This first part will help determine the optimal dose of rebastinib for further testing. In part 2, the safety, tolerability, and efficacy of the recommended dose will be assessed across different groups, including breast cancer, ovarian cancer, and mesothelioma patients. The trial is expected to include up to 117 participants — approximately 18 in the first part, and up to 99 in the second part. “We are extremely pleased with the recent prog
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.